首页> 外文期刊>Translational Oncology >Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment
【24h】

Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment

机译:原发性中枢神经系统淋巴瘤:分子发病机制和治疗进展。

获取原文
       

摘要

Primary central nervous system lymphoma (PCNSL) is a group of extranodal non-Hodgkin lymphoma that exhibits specific biological characteristics and clinical behavior, with an aggressive disease course and unsatisfactory patient outcomes. It is of great importance to identify aberrant genetic loci and important molecular pathways that might suggest potential targets for new therapeutics and provide prognostic information. In this review, we listed various genetic and epigenetic alterations that are involved in PCNSL pathogenesis. In the aspect of treatment, we summarized the related literatures and evaluated the efficacy of surgery, induction chemotherapy, radiotherapy, intrathecal chemotherapy, and autologous stem cell transplantation in PCNSL. We also proposed the possible new agents for recurrent and relapse PCNSL based on the result of recent clinical researches.
机译:原发性中枢神经系统淋巴瘤(PCNSL)是一组结外的非霍奇金淋巴瘤,表现出特定的生物学特征和临床行为,具有侵略性的病程和不令人满意的患者预后。识别异常的基因位点和重要的分子途径对暗示新疗法的潜在靶标并提供预后信息至关重要。在这篇综述中,我们列出了PCNSL发病机制中涉及的各种遗传和表观遗传学改变。在治疗方面,我们总结了相关文献并评估了PCNSL的手术,诱导化疗,放疗,鞘内化疗和自体干细胞移植的疗效。根据最近的临床研究结果,我们还提出了可能的复发和复发PCNSL新药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号